Tag: Non-small cell lung cancer

AstraZeneca reports positive results for phase 2 COAST trial of oleclumab and monalizumab

businessnewstoday- September 18, 2021 0

AstraZeneca has reported positive results from the COAST phase 2 trial of its oleclumab or monalizumab in combination with Imfinzi (durvalumab) in patients with non-small ... Read More

LUMAKRAS FDA approval : Amgen bags approval in KRAS G12C-mutated NSCLC

businessnewstoday- May 29, 2021 0

LUMAKRAS FDA approval : Amgen has bagged accelerated approval from the US Food and Drug Administration (FDA) for LUMAKRAS (sotorasib) for the treatment of a ... Read More

Amgen gets breakthrough therapy status for sotorasib in China

pharmanewsdaily- January 31, 2021 0

Amgen said that sotorasib, an investigational KRASG12C inhibitor, has been given breakthrough therapy designation (BTD) from the Center for Drug Evaluation (CDE) of the National ... Read More

AstraZeneca gets FDA approval for Tagrisso for type of NSCLC

pharmanewsdaily- December 19, 2020 0

AstraZeneca has secured extended approval from the US Food and Drug Administration for using Tagrisso (osimertinib) as an adjuvant treatment of non-small cell lung cancer ... Read More

BMS’ Opdivo plus Yervoy combo gets EC approval for metastatic NSCLC

pharmanewsdaily- November 8, 2020 0

Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of metastatic non-small ... Read More

Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib

pharmanewsdaily- July 15, 2020 0

Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 ... Read More

Selpercatinib FDA approval : Lilly’s therapy approved for treatment of lung and thyroid cancers with RET alteration

pharmanewsdaily- May 9, 2020 0

Selpercatinib FDA approval : The US Food and Drug Administration (FDA) has approved Eli Lilly and Company's Retevmo (selpercatinib) capsules for the treatment of three ... Read More

Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers

pharmanewsdaily- May 9, 2020 0

Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Retevmo (selpercatinib, 40mg and ... Read More

Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC

pharmanewsdaily- December 12, 2019 0

Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) ... Read More

ALTA-1L trial results : Takeda’s ALUNBRIG continues to show superiority over crizotinib

pharmanewsdaily- November 23, 2019 0

ALTA-1L trial results : Takeda Pharmaceutical says that ALUNBRIG (brigatinib), its tyrosine kinase inhibitor (TKI), is continuing to show superiority over crizotinib in the phase ... Read More